Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control Study - Wikidata - wikimedia - TriplyDB

Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control Study

Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control Study

http://www.wikidata.org/entity/Q34369323

about

Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

P2860

Q38665706-819A3FD9-C369-4937-98F5-1B4C8E58FB58 Q39131033-AAA0CA31-14C0-4E15-B6AE-3002EC174C0F

P2860

Gefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control Study

http://www.wikidata.org/entity/Q34369323

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@ast

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@en

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@nl

type

label

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@ast

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@en

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@nl

prefLabel

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@ast

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@en

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@nl

P1433

Q34369323-A0C64674-78C9-4154-AF13-2310E965038B

P1476

Q34369323-03671197-BE41-4A0D-B75D-87479CE8A2EF

P2093

Q34369323-05A34D36-F368-4C9C-8470-9CEC5E528CE7

Q34369323-2CB25C82-5708-4DB1-BF85-64EA438B6FC6

Q34369323-A1381A65-29F8-4267-8F29-13DCCBD7879C

Q34369323-A304C3BF-0196-4BC9-ABF5-D7BFA386A086

Q34369323-AD83FEC6-9DAB-4F03-ADA2-5D7CF083F89D

Q34369323-C470E96D-A8AA-4CE0-A664-E1568AA18F55

Q34369323-DFD86241-6DE9-4432-93ED-E2404C1A5AE7

P2860

Q34369323-03E04B95-EDC7-44E8-B010-09DD8107E41B

Q34369323-082E7C4E-6661-489C-BAAC-A8D22521CDB7

Q34369323-0C07BDF2-275C-4772-95D8-C6FCD1621CDA

Q34369323-0F0B8403-D353-473A-BA9B-30C3AF7B4232

Q34369323-2589FC96-301B-4EE2-AFE9-FCFAECAAB48C

Q34369323-3008DFCF-A9F4-4365-8C87-E5FEC48AAC73

Q34369323-41A7EAA2-A380-49EE-979E-AEAB0B67AD18

Q34369323-4439F9E7-BC0E-47C3-A46D-E405365956B3

Q34369323-55A98752-30C8-4D47-ADF2-152DECF33C42

Q34369323-65BEF2A6-2AEB-4C05-AEB9-963EAE42048F

P304

Q34369323-FADB1F48-87A3-4F38-A897-06EB31ED555B

P31

Q34369323-120993D2-C117-4CD0-A084-60CF74053C29

P356

Q34369323-117CE0DE-774E-473A-848A-720502A90673

P433

Q34369323-23F36469-8895-43A4-8D2F-2764C24B2163

P478

Q34369323-6233A62E-C3CD-4296-A908-F0B29E157CF3

P577

Q34369323-87E50E93-1623-4F7A-96E2-F429EAC7C378

P5875

Q34369323-C1280467-C733-4AC3-A6D7-4F02B18776E9

P698

Q34369323-479437D7-6E89-42FC-9AEA-E49F258C49D2

P921

Q34369323-689FF318-4312-4E0B-BEA3-EC2928C0853B

Q34369323-994BFCA8-E9C3-4AA5-8D91-79CF34E76A44

P932

Q34369323-08270169-D02E-4255-A61C-9EACB6D6A92E

P356

J.TRANON.2014.05.005

P1433

Translational Oncology

P1476

Gefitinib-Integrated Regimen v ...... arcinoma: A Case-Control Study

@en

P2093

Changting Meng

http://www.w3.org/2001/XMLSchema#string

Nan-Jie Zhao

http://www.w3.org/2001/XMLSchema#string

Ning Jia

http://www.w3.org/2001/XMLSchema#string

Xiaohong Ning

http://www.w3.org/2001/XMLSchema#string

Yingyi Wang

http://www.w3.org/2001/XMLSchema#string

Yuzhou Wang

http://www.w3.org/2001/XMLSchema#string

Zhao Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

508-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRANON.2014.05.005

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263323575

http://www.w3.org/2001/XMLSchema#string

P698

24954357

http://www.w3.org/2001/XMLSchema#string

P921

P932

4202800

http://www.w3.org/2001/XMLSchema#string